SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 30, Issue 7, 2012, Pages 759-

High-dose chemotherapy as adjuvant therapy in breast cancer: Could there be a survival benefit?

(1) Moroni, Mauro a

a SAN CARLO BORROMEO HOSPITAL (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LETTER; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84857617901 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2011.39.8057 Document Type: Letter

Times cited : (5)

References (5)

1
- 80051991350
- High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials
- Berry DA, Ueno NT, Johnson MM, et al: High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials. J Clin Oncol 29:3214-3223, 2011
- (2011) J Clin Oncol , vol.29 , pp. 3214-3223
- Berry, D.A.¹ Ueno, N.T.² Johnson, M.M.³

2
- 20244377544
- Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13
- DOI 10.1200/JCO.2005.10.202
- Peters WP, Rosner GL, Vredenburgh JJ, et al: Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23:2191-2200, 2005 (Pubitemid 46222235)
- (2005) Journal of Clinical Oncology , vol.23 , Issue.10 , pp. 2191-2200
- Peters, W.P.¹ Rosner, G.L.² Vredenburgh, J.J.³ Shpall, E.J.⁴ Crump, M.⁵ Richardson, P.G.⁶ Schuster, M.W.⁷ Marks, L.B.⁸ Cirrincione, C.⁹ Norton, L.¹⁰ Henderson, I.C.¹¹ Schilsky, R.L.¹² Hurd, D.D.¹³

3
- 28244478884
- Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial
- DOI 10.1016/S0140-6736(05)67784-7, PII S0140673605677847
- Nitz UA, Mohrmann S, Fischer J, et al: Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 366:1935-1944, 2005 (Pubitemid 41713983)
- (2005) Lancet , vol.366 , Issue.9501 , pp. 1935-1944
- Nitz, U.A.¹ Mohrmann, S.² Fischer, J.³ Lindemann, W.⁴ Berdel, W.E.⁵ Jackisch, C.⁶ Werner, C.⁷ Ziske, C.⁸ Kirchner, H.⁹ Metzner, B.¹⁰ Souchon, R.¹¹ Ruffert, U.¹² Schutt, G.¹³ Pollmanns, A.¹⁴ Schmoll, H.J.¹⁵ Middecke, C.¹⁶ Baltzer, J.¹⁷ Schrader, I.¹⁸ Wiebringhaus, H.¹⁹ Ko, Y.²⁰ more..

4
- 42049121517
- High-dose chemotherapy for patients with high-risk breast cancer: A clinical and economic assessment using a quality-adjusted survival analysis
- DOI 10.1097/COC.0b013e3181573e83, PII 0000042120080400000002
- Marino P, Roché H, Moatti JP, et al: High-dose chemotherapy for patients with high-risk breast cancer: A clinical and economic assessment using a quality-adjusted survival analysis. Am J Clin Oncol 31:117-124, 2008 (Pubitemid 351519162)
- (2008) American Journal of Clinical Oncology: Cancer Clinical Trials , vol.31 , Issue.2 , pp. 117-124
- Marino, P.¹ Roche, H.² Moatti, J.-P.³

5
- 0034699950
- Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomized trial-Scandinavian Breast Group 9401 study
- Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomized trial-Scandinavian Breast Group 9401 study. Lancet 356:1384-1391, 2000
- (2000) Lancet , vol.356 , pp. 1384-1391
- Bergh, J.¹ Wiklund, T.² Erikstein, B.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.